Meeting
2023 ASCO Annual Meeting
Efficacy and safety of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer who had measurable residual disease: A post-hoc subgroup analysis of the PRIME study.
Authors
Beihua Kong
Qilu Hospital of Shandong University, Jinan, China
Beihua Kong , Lingying Wu , Jianqing Zhu , Rutie Yin , Jing Wang , Lingya Pan , Hong Zheng , Jihong Liu , Xiaohua Wu , Li Wang , Yi Huang , Ke Wang , Dongling Zou , Hongqin Zhao , Chunyan Wang , Weiguo Lu , An Lin , Xiaoa Zhen , Wenzhao Hang , Jianmei Hou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT03709316
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5562)
DOI
10.1200/JCO.2023.41.16_suppl.5562
Abstract #
5562
Poster Bd #
257
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer in phase 3 PRIME study: A subgroup analysis by response to first-line platinum-based chemotherapy.
First Author: Rutie Yin
Poster
2021 ASCO Annual Meeting
Efficacy of niraparib maintenance therapy in Chinese women with platinum-sensitive recurrent ovarian cancer with and without secondary cytoreductive surgery: Results from the NORA trial.
First Author: Lingying Wu
Poster
2020 ASCO Virtual Scientific Program
Niraparib exposure-response relationship in patients (pts) with newly diagnosed advanced ovarian cancer (AOC).
First Author: Bradley J. Monk
Poster
2019 ASCO Annual Meeting
Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort.
First Author: Lingying Wu